Recruiting

Testing a New Drug With Standard Chemotherapy for Advanced Lung Cancer

Plain-English translation of NCT05456256 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new medication called , given alongside two standard chemotherapy drugs ( and ), for people with advanced lung adenocarcinoma that has stopped responding to previous targeted treatments. The study will first check that the medication is safe in a small group of 6 patients, then enroll 90 more patients who will randomly receive either the new medication plus chemotherapy or chemotherapy alone. Researchers want to learn whether adding this treatment helps people live longer and control their cancer better.

Many people with advanced lung adenocarcinoma eventually stop benefiting from targeted drugs that work against specific genetic mutations in their cancer. This trial exists to see whether the new treatment, combined with chemotherapy, can help patients whose cancer has progressed despite previous targeted therapy.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced lung adenocarcinoma (stage III or IV) that cannot be removed with surgery
you have specific genetic mutations in your cancer (such as MET, ALK, EGFR, or NTRK changes)
you are a never smoker, or have smoked fewer than 100 cigarettes in your lifetime
your cancer has stopped responding to, or you cannot tolerate, previous targeted drugs called tyrosine kinase inhibitors
you are at least 18 years old and in good enough physical condition to tolerate chemotherapy

You likely don't qualify if…

you have never been treated with a tyrosine kinase inhibitor for your lung cancer
you do not have one of the specific genetic mutations the trial is looking for
you have active seizures or uncontrolled spread of cancer to your brain
you had major surgery or radiation therapy to your tumor less than 30 days ago
your blood counts or liver and kidney function are too low to safely receive chemotherapy

What participation looks like

If you join, you'll first have safety tests to confirm you can receive the treatment. You'll then be randomly assigned to receive either the new medication plus chemotherapy, or chemotherapy alone. Treatment happens once every 21 days for 4 to 6 cycles (about 3 to 4 months total), with the option to continue on chemotherapy maintenance afterward. You'll need regular blood tests and scans to monitor how your cancer responds and check for side effects.

AI-generated summary from trial data · Aug 26, 2026 · Not medical advice

Trial locations(16 sites)

United States

Precision NextGen Oncology and Research Center, Beverly Hills, California

Los Angeles Cancer Network, Fountain Valley, California

Cancer and Blood Specialists Clinic, Los Alamitos, California

Fox Chase Cancer Center, Philadelphia, Pennsylvania

UT Southwestern Medical Center, Dallas, Texas